Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MoonLake ImmunotherapeuticsMLTX · Entity 4785 | Director · Chief Executive Officer | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MoonLake Immunotherapeutics
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 2,774,893 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Sale · Disposed 33,936 · Balance 2,843,182 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 2 · 2026-07-10 · Sale · Disposed 68,289 · Balance 2,774,893 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 13, 2026 20:10 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 68,289 | $20.02 | $1,367,145.78 |
DisclosureSEC source: 0001213900-26-077564 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,774,893 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:10 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 33,936 | $20.01 | $679,059.36 |
DisclosureSEC source: 0001213900-26-077564 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,843,182 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:10 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 47,775 | $20.03 | $956,933.25 |
DisclosureSEC source: 0001213900-26-074964 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,877,118 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2026 Filed Apr 14, 2026 21:55 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 51,873 | $18.23 | $945,644.79 |
DisclosureSEC source: 0001213900-26-043647 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924,893 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 21:55 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 98,127 | $18.41 | $1,806,518.07 |
DisclosureSEC source: 0001213900-26-043647 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,976,766 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantStock Option (Right to Buy) · Derivative | 520,342 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0001213900-26-002906 · ownership.xml · derivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,342 Underlying: Class A ordinary shares, par value $0.0001 per share · 520,342 shares Expires 2036-01-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionCommon shares, par value CHF 0.10 per share, of MoonLake AG · Derivative | 5,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-124510 · ownership.xml · derivative · entry 3 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares, par value $0.0001 per share · 196,316 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest. F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser. F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Disposition to issuerClass C ordinary shares, par value $0.0001 per share | 196,316 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-124510 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest. F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser. F1 · kind: On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionClass A ordinary shares, par value $0.0001 per share | 196,316 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-124510 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,074,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 21:29 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 70,000 | $14.49 | $1,014,300.00 |
DisclosureSEC source: 0001213900-25-120106 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,878,577 F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:29 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 130,000 | $15.08 | $1,960,400.00 |
DisclosureSEC source: 0001213900-25-120106 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,948,577 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:08 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantClass A ordinary shares, par value $0.0001 per share | 95,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-019674 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,078,577 F1 · kind: Represents shares of restricted stock that vest in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 00:56 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 4,740 | $55.89 | $264,918.60 |
DisclosureSEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 3 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,982,814 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:56 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 56,065 | $55.00 | $3,083,575.00 |
DisclosureSEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,987,554 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 00:56 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 62,810 | $55.00 | $3,454,550.00 |
DisclosureSEC source: 0001213900-24-018675 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,043,619 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:48 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 1,125 | $55.27 | $62,178.75 |
DisclosureSEC source: 0001213900-24-016544 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,106,429 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.025 to $55.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2024 Filed Feb 20, 2024 23:36 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 20,000 | $57.44 | $1,148,800.00 |
DisclosureSEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 3 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,107,554 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.115 to $59.21. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:36 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 20,000 | $60.15 | $1,203,000.00 |
DisclosureSEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,127,554 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.335 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:36 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 20,000 | $60.18 | $1,203,600.00 |
DisclosureSEC source: 0001213900-24-015446 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,147,554 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.185 to $63.95. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionCommon shares, par value CHF 0.10 per share, of MoonLake AG · Derivative | 4,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · derivative · entry 6 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,836 Underlying: Class A ordinary shares, par value $0.0001 per share · 140,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest. F4 · security: (continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser. F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionCommon shares, par value CHF 0.10 per share, of MoonLake AG · Derivative | 90,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · derivative · entry 5 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares, par value $0.0001 per share · 3,027,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Disposition to issuerClass C ordinary shares, par value $0.0001 per share | 140,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 4 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,374 F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest. F4 · security: (continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionClass A ordinary shares, par value $0.0001 per share | 140,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 3 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,167,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Disposition to issuerClass C ordinary shares, par value $0.0001 per share | 3,027,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 2 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 23:28 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | ConversionClass A ordinary shares, par value $0.0001 per share | 3,027,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 1 Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,027,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration. F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.